Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771732 | 0.91 | TSHR (0.39) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL29164011 | 0.90 | TSHR (0.42) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL7644505 | 0.89 | TSHR (0.38) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL19029436 | 0.87 | — | — | |
| SCHEMBL23161207 | 0.87 | TSHR (0.36) | TSHRALDH1A1TDP1HSD17B10 | |
| SCHEMBL7644159 | 0.87 | ALDH1A1 (0.39) | TSHRALDH1A1TDP1HSD17B10 | |
| SCHEMBL9428432 | 0.85 | — | — | |
| SCHEMBL28638025 | 0.80 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11217528 | 0.79 | MCL1 (0.31) | TSHR | |
| SCHEMBL13454198 | 0.78 | TSHR (0.46) | TSHRALDH1A1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157998-B1 | MOISTURE-CURABLE POLYMERIC COMPOSITIONS HAVING HALOGENATED POLYMERS AND METAL MERCAPTIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-07-25 | — | — | EP | claimed |
| EP-2334718-B1 | POLY VINYL CHLORIDE FOAM PROMOTERS | PMC ORGANOMETALLIX INC (US) | 2016-02-17 | — | — | EP | claimed |
| CN-101605774-B | 2-methyl-3-(3,4-methylenedioxyphenyl)propanal, and method for production thereof | UBE INDUSTRIES | 2013-05-29 | — | — | CN | claimed |
| CN-101622238-B | Method of retaining the quality of 2-methyl-3-(3,4-methylenedioxyphenyl)propanal and process for producing the same | UBE INDUSTRIES | 2013-05-29 | — | — | CN | claimed |
| CN-101622238-A | Method of retaining the quality of 2-methyl-3-(3,4-methylenedioxyphenyl)propanal and process for producing the same | UBE INDUSTRIES | 2010-01-06 | — | — | CN | claimed |
| CN-101605774-A | 2-methyl-3-(3, the 4-methylene dioxy phenyl group) propionic aldehyde and manufacture method thereof | UBE INDUSTRIES (JP) | 2009-12-16 | — | — | CN | claimed |
| CN-100336811-C | Method for preparing 1-acetoxyl-3- (substituted phenyl) propylene compound | UBE INDUSTRIES (JP) | 2007-09-12 | — | — | CN | claimed |
| EP-1574509-B1 | PROCESS FOR THE PRODUCTION OF 1-ACETOXY-3-(SUBSTITUTED PHENYL)PROPENES | UBE INDUSTRIES (JP) | 2007-06-13 | — | — | EP | claimed |
| US-7173148-B2 | Process for producing 1-acetoxy-3-(substituted phenyl)propene compound | UBE INDUSTRIES, LTD. (JP) | 2007-02-06 | — | — | US | claimed |
| US-20060069273-A1 | Process for producing 1-acetoxy-3-(substituded phenyl) propenes | UBE INDUSTRIES, LTD. (JP) | 2006-03-30 | — | — | US | claimed |
| CN-1738811-A | Method for preparing 1-acetoxyl-3- (substituted phenyl) propylene compound | UBE INDUSTRIES (JP) | 2006-02-22 | — | — | CN | claimed |
| EP-1574509-A1 | PROCESS FOR THE PRODUCTION OF 1-ACETOXY-3-(SUBSTITUTED PHENYL)PROPENES | Ube Industries, Ltd. (JP) | 2005-09-14 | — | — | EP | claimed |
| EP-1115787-B1 | HALOGEN CONTAINING POLYMER COMPOUNDS CONTAINING MODIFIED ZEOLITE STABILIZERS | NOVEON IP HOLDINGS CORP (US) | 2004-11-24 | — | — | EP | claimed |
| EP-0977742-B1 | THE PREPARATION OF ENANTIOMERICALLY ENRICHED OXAZOLONES AND ALPHA, ALPHA-DISUBSTITUTED AMINO ACIDS | UNIV LELAND STANFORD JUNIOR (US) | 2003-09-10 | — | — | EP | claimed |
| EP-1044205-A4 | CHEMICAL ACETYLATION OF DESACETYL-CEPHALOSPORINS | BRISTOL MYERS SQUIBB CO (US) | 2001-12-05 | — | — | EP | claimed |
| EP-1044205-A1 | CHEMICAL ACETYLATION OF DESACETYL-CEPHALOSPORINS | Bristol-Myers Squibb Company (US) | 2000-10-18 | — | — | EP | claimed |
| EP-0977742-A1 | THE PREPARATION OF ENANTIOMERICALLY ENRICHED OXAZOLONES AND ALPHA, ALPHA-DISUBSTITUTED AMINO ACIDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-02-09 | — | — | EP | claimed |
| US-5917032-A | ACETYL DONOR AND DICYCLOHEXYLAMINE ACTIVATOR OR CATALYST. | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-29 | — | — | US | claimed |
| WO-1999023098-A1 | CHEMICAL ACETYLATION OF DESACETYL-CEPHALOSPORINS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-14 | — | — | WO | claimed |
| WO-1998046578-A1 | THE PREPARATION OF ENANTIOMERICALLY ENRICHED OXAZOLONES AND α,α-DISUBSTITUTED AMINO ACIDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-10-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069273-A1 | Process for producing 1-acetoxy-3-(substituded phenyl) propenes | AKR1C4, PAH, AKR1C3 | TSHR 1110/4885ALDH1A1 239/4885CHRM2 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.